Introduction: Retinopathy of Prematurity (ROP) is a disease observed in extremely premature infants characterized by visioning-threatening retinal vessel proliferation. Propranolol, a drug used for decades in newborn infants with heart diseases, hypertension and thyrotoxicosis and licensed for infantile hemangiomas, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies. Methods and analysis: ROPROP is an investigator-initiated, multicenter placebo-controlled double-blind randomized controlled trial aiming to assess the safety and efficacy of orally administered propranolol to reduce the risk of threshold ROP (stage 3) in extremely preterm infants at 48 weeks postmenstrual age (primary objective) and the rate of infants requiring local interventions for severe retinopathy of prematurity (secondary objective). Key inclusion criteria: Gestational age < 28 weeks, birth weight < 1,250 g, postmenstrual age ≥31 and <37 
Ethics and dissemination.
The protocol has received ethical and regulatory approval. Results will be published after peer-review irrespective of the study outcome.
Trial Registration Numbers: NCT03083431 (www.ClinicalTrials.gov), EudraCT# 2017-002124-24 (EUCTR), 00013730 (DRKS).

Strenghts and limitations of the study
• Repurposing of a well-known drug for a rare disease
• Large, multicenter trial addressing a major public health concern
• No commercial interests (investigator-initiated, funded by public agencies)
• worldwide available as a generic medication without age restrictions. Its long-standing indications include treatment of high blood pressure, a number of types of irregular heart rate, thyrotoxicosis, migraine prophylaxis, performance anxiety, and essential tremor. In infants and children, propranolol is used for prevention of paroxysmal supraventricular tachycardia, prevention of sudden ventricular fibrillation in long QT-syndrome, prevention of blue spells in tetralogy of Fallot, and treatment of hypertension in children with renal or cardiovascular disease. Moreover, propranolol has been found to lead to the regression of infantile hemangiomas and has been licensed in 2014 for this purpose in the European Union, Switzerland and the United States.
Retinopathy of prematurity (ROP) is a disorder of the developing retina observed only in low birth weight preterm infants that may lead to blindness in a small but significant percentage of those infants. In preterm infants, retinal vessels are incompletely developed at birth and display a growth spurt peaking around 4-8 weeks before due term. Ophthalmoscopies performed during this growth spurt may reveal abnormal proliferation of blood vessels that recede once vascularization is complete. If the neovascularization, however, progresses to extraretinal fibrovascular proliferation into the vitreous (threshold ROP), there is a high risk of retinal detachment with subsequent blindness. Threshold ROP is associated with polymorphisms in a variety of genes, none of which cause retinopathy in the absence of prematurity. Vision-threatening ROP affects 10-15% of extremely preterm infants with a gestational age below 28 weeks (0.7% of all newborns), with an overall incidence of about 5 cases per 1,000,000 inhabitants (orphan disease).
Currently available treatment of threshold ROP, consisting of laser ablation of the peripheral retina or intravitreal injection of antagonists of vascular endothelial growth factor (VEGF), may prevent most but not all cases of permanent ROP-mediated blindness. Treated ROP is a strong independent predictor of later neurodevelopmental impairment in childhood and adolescence. [3] [4] [5] Both types of local treatment are associated with significant costs and side effects. 6 Ablative laser surgery leads to permanent destruction of the peripheral retina (scars) while normal-appearing peripheral retinal vessels have been found to continue after intravitreal treatment. A large randomized controlled trial has shown superior short-term and long-term results for intravitreal injections of the anti-VEGF antibody, bevacizumab, as compared to laser treatment. 7 8 Intravitreal bevacizumab treatment, however, is completely off-label, as the antibody is not manufactured for intravitreal use and has never been licensed for infants. Other anti-VEGF antagonists made for intravitreal administration (ranibizumab, pegabtanib, aflibercept) are also not licensed in infants and have never been tested in The pathophysiological pattern of ROP is reminiscent to the natural history of infantile hemangiomas which are also more common in preterm infants. Preliminary results from two open-label comparison studies 9 10 and three randomized controlled trials (RCT) [11] [12] [13] An overview of published results of trials is given in Table 1 . • IRCT2015102524681N1 is a parallel-assignment non-placebo-controlled trial from Guilen, Iran, for infants with early stages of ROP using oral propranolol at 2 mg/kg/day divided in 4 doses for infants with a gestational age of 26-31 weeks and 1mg/kg/day divided in 4 doses for infants with a gestational age of 23-25 weeks (target sample size, n=50). Recruitment started in 2015 and is ongoing.
• NCT02977000 is a single-group assignment trial from Zhengzhou, China that treats preterm newborns with a gestational age below 32 weeks and stage 2 ROP with oral propranolol (target sample size, n=100). Recruitment started in 2016 and is ongoing.
• NCT03038295 is placebo-controlled RCT from Guangdong, China, comparing oral propranolol 
Methods and analysis
Patients
Each patient must meet all of the following criteria to be enrolled in the trial:
• Preterm infant born before 28 weeks gestation
• Birth weight below 1250 g
• Alive at 5 weeks of age
• Postmenstrual age 31 0 / 7 -36 6 / 7 weeks
• Ophthalmoscopic evidence of incipient ROP (stage 1 or 2, with or without plus disease)
• Written informed consent by parents or legal guardian, including saving and propagation of pseudonymous medical data for study purposes.
Patients meeting any of the following criteria are not eligible for enrollment:
• ROP stage 3 at time of inclusion (endpoint already reached)
• Thyrotoxicosis, arterial hypertension or congenital heart diseases requiring open-label propranolol treatment (such as tetralogy of Fallot, paroxysmal supraventricular tachycardia, or long QT syndrome)
• Atrio-ventricular block grade 2 or 3 (contraindication for propranolol)
• Sinuatrial block (contraindication for propranolol)
• Uncontrolled heart failure or cardiogenic shock (contraindication for propranolol)
• Acute severe infection (inclusion may be postponed until infection has resolved)
• Bronchial asthma
• Major congenital malformations or known chromosomal anomalies
• Colobomas and other eye malformations
• PHACE syndrome (posterior fossa anomalies, large infantile hemangiomas of the face, neck, and/or scalp, arterial lesions, cardiac abnormalities/coarctation of the aorta, eye anomalies) (risk of cerebrovascular complications)
• Very large hemangioma (risk of hyperkalemia), as judged by the attending physician
• Heart rate consistently (> 1h) < 100/min 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y • Noninvasive mean arterial pressure consistently (> 1h) < 40 mmHg
• Medication of the infant or the mother if breastfeeding with clonidine, reserpine, angiotensinconverting enzyme inhibitors, angiotensin-receptor antagonists (contraindicated in preterm infants) or antiarrhythmic drugs including amiodarone, propafenone, lidocaine, digoxin/digitoxin, quinidine, verapamil, diltiazem, bepridil (pharmacodynamic interaction)
• Medication of the infant with rifampicin or phenobarbitone (enhanced metabolic clearance)
• Concurrent treatment with insulin (risk of hypoglycemia)
• Severe liver dysfunction (GPT > 900 U/L)
• Chronic kidney impairment (serum creatinine > 1.3 mg/dl [100 µM])
• Persistent hypoglycemia (blood glucose < 36 mg/dl [2.0 mM] in 3 consecutive samples immediately preceding enrollment)
• Persistent hyperkalemia (venous serum potassium > 5.9 mM in 3 consecutive samples immediately preceding enrollment)
• Persistent neutropenia (absolute neutrophil counts < 1,000/µL in 3 consecutive samples immediately preceding enrollment)
• Known hypersensitivity to propranolol or any of the excipients
• Prinzmetal's angina, Raynaud's phenomenon (severe peripheral arterial circulatory disturbance), or pheochromocytoma (contraindications for propranolol in adults, not occurring in newborn infants)
• Participating in another pharmacological interventional clinical trial
• Any circumstances that make the investigator believe that participation in the study leads to exceptional medical or organizational problems for the patient.
Intervention and Comparator
The intervention consists of oral propranolol (1.6 mg propranolol hydrochloride/kg·d in 3-4 divided dosages) given for 4-10 weeks (depending on postmenstrual gestational age at birth) or placebo. The study medication (1 mg/ml propranolol hydrochloride solution or placebo) will be provided and labeled by the GMP-licensed University Pharmacy of Erlangen, Germany, as a sterile solution in screw-capped vials. The oral solution contains sucrose (25 g/100 ml), potassium sorbate (0.15 g/100 ml), citric acid monohydrate (0.07 g/100 ml), orange flavor and distilled water as excipients. The vials are stored at room temperature. The solution is drawn into a syringe and administered by mouth or gastric gavage together with feeds. If the infant does not drink the medication, it will be given by gavage, but there is no replacement dose in case an infant vomits. If enteral feeding is stopped completely for any reason, the study medication will be temporarily discontinued and gradually resumed when enteral feeding is reinstituted. Once an infant is switched to feeding every 4 h, the total dose may be divided in three divided dosages (i.e. every 8 ± 2 h). The duration of the study medication treatment is limited to 10 weeks. The study drug is reduced by 50% and discontinued the following day prior to discharge, when a decision has been made for local ROP treatment, or when the infants is scheduled for surgery (e.g. for inguinal hernia repair). No study medication will be given to patients out of hospital.
The study medication will be discontinued temporarily in the event of a lower respiratory infection associated with dyspnea and wheezing or for any adverse clinical symptoms, as decided by the attending physicians. As soon as symptoms resolve, the maintenance dose is to be resumed, but reduced by 50% and readjusted to the original dose after three days. Attending physicians can hold or decrease doses of study drugs at their discretion in case of worsening disease or recurring adverse clinical symptoms. The study medication will permanently discontinued in the event of isolated bronchospasm or severe liver disease.
The following drugs may not be given concomitant with the study medication: Antiarrhythmic drugs (all classes including amiodarone, propafenone, lidocaine, digoxin/digitoxin, and calcium channel blockers), clonidine, reserpine, angiotensin converting enzyme inhibitors/angiotensin receptor antagonists (contraindicated in preterm infants), inhalational anesthetics (except during emergencies), rifampicin, phenobarbitone.
If an infant requires open-label propranolol during the study, the infant will be taken off the study drug, and the data will censored for the efficacy analysis.
If a mother who breastfeeds her infant starts taking propranolol, steroids, rifampicin, or phenobarbitone, the investigator will be informed while breastfeeding may continue. It will be recorded but this does not imply discontinuation of the study and will not change the primary or secondary efficacy analysis which is by intention to treat.
If a mother who breastfeeds her infants starts to take antiarrhythmic drugs (all classes including amiodarone, propafenone, lidocaine, digoxin/digitoxin, and calcium channel blockers), clonidine, reserpine, angiotensin-converting enzyme inhibitors or angiotensin-receptor antagonists, the infant will be taken off the study drug, and the data will censored for the efficacy analysis. occur before ROP has progressed to its peak stage.
Outcome and Time frame
The secondary endpoint for efficacy is survival until 48 weeks postmenstrual age without local treatment for ROP (ablative laser surgery or intravitreal injections of anti-VEGF agents). Treated ROP is associated with neurodevelopmental impairment at 2, 5 and 11 years of age. [3] [4] [5] Safety is gauged by the incidence of the following major events: Death, necrotizing enterocolitis Exploratory continuous-scale secondary outcomes are duration of supplemental oxygen and duration of hospitalization (relative to the date of due term delivery), lowest heart rate and mean arterial pressure while the infant received study medication, average relative gain of weight and head circumference between start and end of the study medication.
Sample size calculation
The ROPROP study is designed to demonstrate the superiority of oral propranolol in comparison to placebo in increasing the rate of infants surviving to 48 weeks postmenstrual age without threshold ROP (primary endpoint). Assuming a rate of 30% of infants who will progress to threshold ROP or die, 18 262 infants (131 in each group) will have to be analyzed to have 80% power (at a two-sided alpha level of 5%) to detect a 50% lower risk in the treatment group (two-sided Fisher exact testbased calculations, G*power 3.1.9.2., 2014). 19 With an anticipated loss to follow-up of 5%
(withdrawal or other reasons), the total number of infants allocated to treatment will be 276.
Assuming that 10% of eligible patients will not be recruited for lack of parental consent and 3% for medical or organizational exclusion criteria, a total of 312 patients will be assessed for eligibility. This translates to 624 patients screened by fundoscopy, assuming a rate of incipient ROP of 50%, and 718 
Statistical analysis plan
The confirmatory analysis of the primary efficacy endpoint is by intention-to-treat, based on all patients who were randomized according to the inclusion and exclusion criteria and who received at least one dose of the study medication.
The proportion of infants who have reached the primary endpoint will be compared and statistically assessed by means of a two-sided Fisher exact test to examine the null hypothesis of equal proportions in the groups of infants allocated to placebo and to oral propranolol, respectively. The effect size will be described by calculating relative risks and 95% confidence intervals. To consider the influence of center and gestational age (< 26 weeks vs ≥ 26 weeks), these variables will be included in to a logistic regression analysis. Survival without threshold ROP will be the dependent variable while treatment group, center and gestational age will be the independent variables. To handle patients with unknown status of the primary endpoint, a sensitivity analysis will be carried out in three steps:
(1) patients with missing values excluded; (2) patients with missing values included, primary endpoint 'yes'; (3) patients with missing values, primary endpoint 'no' (best and worst case scenario). While the confirmatory analysis will be based on the intention-to-treat principle, a per protocol analysis will be conducted in addition.
The secondary endpoint for efficacy and dichotomous endpoints for safety will be compared and statistically assessed for descriptive purposes and not in a confirmatory sense (explorative data analysis, no hypothesis testing). Therefore, p values of these variables will not be adjusted for multiple testing. In addition to a pre-specified subgroup analysis (infants < 26 weeks versus ≥ 26 weeks gestational age), exploratory subgroup analyses will be done by logistic regression analysis.
The distribution of dichotomous variables will be compared employing the Fisher exact test, and relative risks with 95% confidence intervals will be calculated.
The distribution of continuous variables will be compared by the Wilcoxon test. Censored data will be analyzed with the use of Kaplan-Meier estimates and compared by the log-rank test. Hazard ratios will be calculated with the use of Cox regression.
The significance level in all tests will be set at 0.05.
Summary tables will list discrete variables by absolute and relative frequencies, continuous variables will be given by median, minimum, maximum and interquartile range. One formal interim analysis for efficacy is planned, after half of the patients have been enrolled in the trial and have reached 48 weeks gestational age. The statistical observation will be done for a significance level of 0.001 (two-sided) (adjustment according to Peto-Haybittle). The interim analyses will be conducted by a statistician using coded group labels A and B blinded for the actual therapy groups.
To allow for patient-level meta-analyses, de-identified individual participant data that underlie the results reported will be supplied to investigators whose proposed use of the data has been approved by an independent review committee (learned intermediary) during a limited period of time for individual participant data meta-analysis. For strict de-identification, only year of birth (instead of date of birth), country (but not site) and birth weight category (by 100 g-intervals) will be allowed.
Ethics and dissemination
The protocol has received ethical (lead ethical committee: Ethikkommission Landesamt für Berlin.
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Iran, for infants with early stages of ROP using oral propranolol at 2 mg/kg/day divided in 4 113 doses for infants with a gestational age of 26-31 weeks and 1mg/kg/day divided in 4 doses 114 for infants with a gestational age of 23-25 weeks (target sample size, n=50). Recruitment 115 started in 2015 and is ongoing. 116
• NCT02977000 is a single-group assignment trial from Zhengzhou, China that treats preterm 117 newborns with a gestational age below 32 weeks and stage 2 ROP with oral propranolol 118 (target sample size, n=100). Recruitment started in 2016 and is ongoing. 119
• NCT03038295 is placebo-controlled RCT from Guangdong, China, comparing oral propranolol 120 (0.25 mg/kg/d) and propranolol eye drops (0.2%) versus placebo in preterm infants below 121 • Atrio-ventricular block grade 2 or 3 (contraindication for propranolol) 153
• Sinuatrial block (contraindication for propranolol) 154
• Uncontrolled heart failure or cardiogenic shock (contraindication for propranolol) 155
• Acute severe infection (inclusion may be postponed until infection has resolved) 156
• Bronchial asthma 157
• Major congenital malformations or known chromosomal anomalies 158
• Colobomas and other eye malformations 159
• PHACE syndrome (posterior fossa anomalies, large infantile hemangiomas of the face, neck, 160 and/or scalp, arterial lesions, cardiac abnormalities/coarctation of the aorta, eye anomalies) (risk 161 of cerebrovascular complications) 162
• Very large hemangioma (risk of hyperkalemia), as judged by the attending physician 163 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 9 groups, the patients will be randomized, with stratification of center and gestational age. This 198 randomization will be done centrally using the randomization tool within the study software 199 secuTrial®. The randomization scheme incorporating variance minimization will be used to assign 200 infants, in a 1:1 ratio, to verum or placebo, with stratification according to gestational age 201 (< 26 weeks vs ≥ 26 weeks) and study site. Sequences of patient numbers will be assigned to each 202 study center and kept confidential, using sequentially numbered blinded medication boxes. The 203 study medication (propranolol or placebo) will be randomly assigned to each patient number. Each 204 IMP bottle has a unique medication number in the study medication list (unblinded) and will be 205 manually linked to the assigned random patient number. The randomization documentation ("key 206 list") is subject to monitoring. Treatment allocation will only be known to the pharmacist and the 207 unblinded person. Neither the neonatologists taking care of the baby, nor the ophthalmologists 208 performing the opthalmoscopies (the actual outcome assessors) will be aware of the assignment. 209
210
Intervention and Comparator 211
The intervention consists of oral propranolol (1.6 mg propranolol hydrochloride/kg·d in 3-4 divided 212 dosages) given for 4-10 weeks (depending on postmenstrual gestational age at birth) or placebo. The 213 study medication (1 mg/ml propranolol hydrochloride solution or placebo) will be provided and 214 labeled by the GMP-licensed University Pharmacy of Erlangen, Germany, as a solution in screw-215 capped bottles. The oral solution contains sucrose (25 g/100 ml), potassium sorbate (0.15 g/100 ml), 216 citric acid monohydrate (0.07 g/100 ml), orange flavor and distilled water as excipients. The bottles 217 are stored at room temperature. The solution is drawn into a syringe and administered by mouth or 218 gastric gavage together with feeds. If the infant does not drink the medication, it will be given by 219 gavage, but there is no replacement dose in case an infant vomits. If enteral feeding is stopped 220 completely for any reason, the study medication will be temporarily discontinued and gradually 221 resumed when enteral feeding is reinstituted. 222
The starting dose is 0.4 mg/kg/d [=0.4 ml/kg/d] by mouth or gavage in four divided dosages (i.e. 223 every 6 ± 1.5 h) together with feeds, followed by incremental increases by 0.4 mg/kg every other day 224 to a final dose of 1.6 mg/kg/d (concentrations pertain to propranolol hydrochloride, to convert into 225 propranolol base, multiply by 0.878). Once an infant is switched to feeding every 4 h, the total dose 226 may be divided in three divided dosages (i.e. every 8 ± 2 h). The duration of the study medication 227 treatment is limited to 10 weeks. The study drug is reduced by 50% and discontinued the following 228 day prior to discharge, when a decision has been made for local ROP treatment, or when the infants 229 is scheduled for surgery (e.g. for inguinal hernia repair). No study medication will be given to patients 230 out of hospital. 231
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If an infant requires open-label propranolol during the study, the infant will be taken off the study 244 drug, and the data will censored for the efficacy analysis. 245
If a mother who breastfeeds her infant starts taking propranolol, steroids, rifampicin, or 246 phenobarbitone, the investigator will be informed while breastfeeding may continue. It will be 247 recorded but this does not imply discontinuation of the study and will not change the primary or 248 secondary efficacy analysis which is by intention to treat. 249
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The secondary endpoint for efficacy is survival until 48 weeks postmenstrual age without local 265 treatment for ROP (ablative laser surgery or intravitreal injections of anti-VEGF agents). Treated ROP 266 is associated with neurodevelopmental impairment at 2, 5 and 11 years of age. [3] [4] [5] 267 Safety is gauged by the incidence of the following major events: Death, necrotizing enterocolitis 268 (requiring surgery), culture-proven sepsis or meningitis (defined as growth of a recognized pathogen 269 not counting coagulase-negative staphylococci in blood or cerebrospinal fluid in an infant treated for 270 at least 5 d with intravenous antibiotics and a rise of C-reactive protein to more than 10 mg/l during 271 the first 72 h of antibiotic treatment), symptomatic hypoglycemia (blood glucose < 30 mg/dl 272 requiring intravenous glucose administration for 48 h or more), and emergency endotracheal 273 intubation (excluding elective intubation for surgery). 274
Exploratory continuous-scale secondary outcomes are duration of supplemental oxygen and duration 275 of hospitalization (relative to the date of due term delivery), lowest heart rate and mean arterial 276 pressure while the infant received study medication, average relative gain of weight and head 277 circumference between start and end of the study medication. 278
279
Sample size calculation 280
The ROPROP study is designed to demonstrate the superiority of oral propranolol in comparison to 281 placebo in increasing the rate of infants surviving to 48 weeks postmenstrual age without threshold 282 ROP (primary endpoint). Assuming a rate of 30% of infants who will progress to threshold ROP or 283 die, 21 262 infants (131 in each group) will have to be analyzed to have 80% power (at a two-sided 284 alpha level of 5%) to detect a 50% lower risk in the treatment group (two-sided Fisher exact test-285 based calculations, G*power 3.1.9.2., 2014). 22 With an anticipated loss to follow-up of 5% 286 (withdrawal or other reasons), the total number of infants allocated to treatment will be 276. 287
Assuming that 10% of eligible patients will not be recruited for lack of parental consent and 3% for 288 medical or organizational exclusion criteria, a total of 312 patients will be assessed for eligibility. This 289 translates to 624 patients screened by fundoscopy, assuming a rate of incipient ROP of 50%, and 718 290 infants below 28 weeks gestational age admitted to neonatal care, assuming an early mortality rate 291 of 15%. 292
293
Statistical analysis plan 294
The ROPROP study is designed to demonstrate the superiority of oral propranolol in comparison to 295 placebo in increasing the rate of infants surviving to 48 weeks postmenstrual age without ROP stage 296 3 or more (primary endpoint
Null hypothesis: 298
There is no difference in the rate of infants surviving to 48 weeks postmenstrual age without ROP 299 stage 3 or more between infants treated with oral propranolol and infants treated with placebo. 300
Alternative hypothesis: 301
There is a difference in the rate of infants surviving to 48 weeks postmenstrual age without ROP 302 stage 3 or more between infants treated with oral propranolol and infants treated with placebo. 303
The following populations will be described and analyzed: 304
• The screened population will comprise all screened patients. The screened population will be 305 described in terms of the reasons for exclusion from randomization. No analysis will be done for 306 the screened population. 307
• The intention-to-treat population (ITT) includes all randomized patients who received at least 308 one dose of the study medication, with the exception of patients who are randomized in 309 contradiction to one of the inclusion or exclusion criteria.; 310
• The 'Per Protocol population' (PPP) will be based on the ITT. Patients treated with open-label 311 oral propranolol will be excluded from the PPP. 312
• The safety population will include all infants who ever received the study drug. 313
The primary and secondary endpoints will be analyzed in the ITT und PPP, while safety endpoints will 314 be analyzed in the safety population. 315
The primary endpoint for efficacy is survival until 48 weeks postmenstrual age without ROP stage 3 316 or more (any zone), as diagnosed according to the International Committee for the Classification of 317
Retinopathy of Prematurity (ICROP) Revisited (12) . The proportion of infants who have reached the 318 primary endpoint will be compared and statistically assessed by means of a two-sided Fisher exact 319 test to examine the null hypothesis of equal proportions in the groups of infants allocated to placebo 320 and to oral propranolol, respectively. Effect sizes will be described by calculating the relative risk as 321 well as the odds ratio and 95% confidence intervals. 322
The confirmatory analysis of the primary efficacy endpoint will be by intention-to-treat, based on all 323 patients who were randomized according to the inclusion and exclusion criteria and who received at 324 least one dose of the study medication. 325
To consider the influence of site and gestational age (< 26 weeks vs ≥ 26 weeks), these variables will 326 be included in to a logistic regression analysis. Survival until week 48 without ROP stage 3 or more 327 will be the dependent variable while treatment group, site and gestational age will be the 328 independent variables. 329 primary endpoint 'no' (sensitivity analysis) (best and worst case scenario). 333
The secondary endpoint for efficacy is survival until 48 weeks postmenstrual age without local 334 treatment for ROP (ablative laser therapy or intravitreal injections of anti-VEGF agents). It will be 335 analyzed analogously to the primary endpoint. 336
The parameters for assessing safety are rates of death prior to discharge, necrotizing enterocolitis 337 (requiring surgery), culture-proven sepsis or meningitis (defined as growth of a recognized pathogen 338 not counting coagulase-negative staphylococci in blood or cerebrospinal fluid in an infant treated at 339 least five days with intravenous antibiotics and a rise of C-reactive protein to more than 10 mg/l 340 during the first 72 h of antibiotic treatment), symptomatic hypoglycemia (blood glucose < 30 mg/dl 341 requiring intravenous glucose administration), and emergency endotracheal intubation (excluding 342 intubation for surgery). 343
Continuous-scale safety outcomes are duration of supplemental oxygen and duration of 344 hospitalization (relative to the date of due term delivery), lowest heart rate and mean arterial 345 pressure while the infant received study medication, average weekly gain of weight and head 346 circumference between start and end of the study medication. 347 Summary tables will list discrete variables by absolute and relative frequencies, continuous variables 348 will be given by median, minimum, maximum and interquartile range for each treatment group. 349 Discrete variables will be compared using Fisher's exact tests, while continuous variables will be 350 compared by the Wilcoxon test. 351
AEs and SAEs will be analyzed descriptively per group using absolute and relative frequencies. 352
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Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Strategies for achieving adequate participant enrolment to reach target sample size
Methods: Assignment of interventions (for controlled trials)
Allocation:
Method of generating the allocation sequence (eg, computergenerated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions Allocation concealment mechanism 16b P 7.4 M p8 L188-p8 L209
Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned Implementation 16c P 7.4 M p8 L188-p8 L209
Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions Blinding (masking) 17a P 6.9 M p8 L188-p8 L209
Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 17b P 6.10
If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial Definition of analysis population relating to protocol nonadherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
Methods: Monitoring
Data monitoring 21a P 10.9
Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed 21b P 13.2.5
Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
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